HQL (abrdn Life Sciences Investors) Cash-to-Debt: N/A (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HQL abrdn Life Sciences Investors HQL
51 GF Score
Price $22.08
GF Value $62.01
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is abrdn Life Sciences Investors Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. abrdn Life Sciences Investors's cash to debt ratio for the quarter that ended in Mar. 2026 was N/A.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for abrdn Life Sciences Investors's Cash-to-Debt or its related term are showing as below:

During the past 9 years, abrdn Life Sciences Investors's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

HQL's Cash-to-Debt is not ranked *
in the Asset Management industry.
Industry Median: 5.63
* Ranked among companies with meaningful Cash-to-Debt only.

abrdn Life Sciences Investors  (NYSE:HQL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

abrdn Life Sciences Investors Cash-to-Debt Related Terms

abrdn Life Sciences Investors Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for abrdn Life Sciences Investors's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

abrdn Life Sciences Investors Cash-to-Debt Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only No Debt N/A N/A N/A No Debt

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A No Debt N/A

HQL vs IIM, NOAH, FAX: Cash-to-Debt Comparison

For the Asset Management subindustry, abrdn Life Sciences Investors's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

abrdn Life Sciences Investors Cash-to-Debt vs Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's Cash-to-Debt falls into.


HQL
51GF Score
abrdn Life Sciences Investors HQL
Cash-to-Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

abrdn Life Sciences Investors Cash-to-Debt Calculation

This is the ratio of a company's Balance Sheet Cash And Cash Equivalents to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

abrdn Life Sciences Investors's Cash to Debt Ratio for the fiscal year that ended in Sep. 2025 is calculated as:

abrdn Life Sciences Investors had no debt (1).

abrdn Life Sciences Investors's Cash to Debt Ratio for the quarter that ended in Mar. 2026 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?

Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued. The current stock price of $22.08 is trading 64.4% below its estimated GF Value™ of $62.01. GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.

Key valuation signals for HQL:

  • Cash-to-Debt: N/A
  • GF Value™: $62.01 vs. price of $22.08 (64.4% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

abrdn Life Sciences Investors Business Description

Address 1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score

Get the complete analysis for HQL

Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.08
Price
$62.01
GF Value